|Mr. Gregory J. Flesher||CEO & Director||N/A||N/A||1970|
|Dr. Catherine C. Turkel||Pres||N/A||N/A||1961|
|Mr. Jon S. Kuwahara CPA, CPA||Sr. VP of Fin. & Admin.||N/A||N/A||1965|
Novus Therapeutics, Inc., a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.
Novus Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.